These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 24509625)

  • 1. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
    Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
    Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
    PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
    Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J
    Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
    Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
    Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
    Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT
    Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma.
    Xu W; Kim JW; Jung WJ; Koh Y; Yoon SS
    Cancer Res Treat; 2018 Apr; 50(2):599-613. PubMed ID: 28675026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
    Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
    Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.
    Redaelli S; Ceccon M; Antolini L; Rigolio R; Pirola A; Peronaci M; Gambacorti-Passerini C; Mologni L
    Oncotarget; 2016 Nov; 7(45):72886-72897. PubMed ID: 27662658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.
    Zhang S; Wang F; Keats J; Zhu X; Ning Y; Wardwell SD; Moran L; Mohemmad QK; Anjum R; Wang Y; Narasimhan NI; Dalgarno D; Shakespeare WC; Miret JJ; Clackson T; Rivera VM
    Chem Biol Drug Des; 2011 Dec; 78(6):999-1005. PubMed ID: 22034911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma.
    Hamedani FS; Cinar M; Mo Z; Cervania MA; Amin HM; Alkan S
    Leuk Res; 2014 Apr; 38(4):503-8. PubMed ID: 24486291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
    Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
    Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.
    Mologni L; Ceccon M; Pirola A; Chiriano G; Piazza R; Scapozza L; Gambacorti-Passerini C
    Oncotarget; 2015 Mar; 6(8):5720-34. PubMed ID: 25749034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.
    Debruyne DN; Bhatnagar N; Sharma B; Luther W; Moore NF; Cheung NK; Gray NS; George RE
    Oncogene; 2016 Jul; 35(28):3681-91. PubMed ID: 26616860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.
    Ceccon M; Mologni L; Giudici G; Piazza R; Pirola A; Fontana D; Gambacorti-Passerini C
    Mol Cancer Res; 2015 Apr; 13(4):775-83. PubMed ID: 25421750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
    Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
    BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
    Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA
    Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.